1. Home
  2. SPHR vs ABCL Comparison

SPHR vs ABCL Comparison

Compare SPHR & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sphere Entertainment Co.

SPHR

Sphere Entertainment Co.

HOLD

Current Price

$103.93

Market Cap

4.8B

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

SELL

Current Price

$12.65

Market Cap

4.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
SPHR
ABCL
Founded
2020
2012
Country
United States
Canada
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.1B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
SPHR
ABCL
Price
$103.93
$12.65
Analyst Decision
Buy
Strong Buy
Analyst Count
13
12
Target Price
★ $169.08
$16.82
AVG Volume (30 Days)
829.6K
★ 4.9M
Earning Date
11-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 113.03
10.91
EPS
N/A
★ N/A
Revenue
★ $1,220,045,000.00
$75,128,000.00
Revenue This Year
$11.02
N/A
Revenue Next Year
$0.05
$7.12
P/E Ratio
★ N/A
N/A
Revenue Growth
18.81
★ 160.56
52 Week Low
$58.18
$2.75
52 Week High
$181.63
$14.98

Technical Indicators

Market Signals
Indicator
SPHR
ABCL
Relative Strength Index (RSI) 22.96 52.08
Support Level $89.02 $11.78
Resistance Level $119.30 $12.88
Average True Range (ATR) 6.25 0.83
MACD -2.82 -0.24
Stochastic Oscillator 5.14 27.97

Price Performance

Historical Comparison
SPHR
ABCL

About SPHR Sphere Entertainment Co.

Sphere Entertainment Co is a live entertainment and media company. The firm creates, writes, casts, produces, and tours shows and events. The group has two reportable segments: Sphere and MSG Networks. Sphere is a next-generation entertainment medium, and MSG Networks operates two regional sports and entertainment networks, as well as a direct-to-consumer (DTC) and authenticated streaming product.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: